Share
Not all products are available in the USA. Click here for a regulatory status overview.
Kidney

Protect your patient’s kidneys

Rhabdomyolysis results in release of myoglobin into the bloodstream. Excessive myoglobin can accumulate in the kidneys and lead to acute kidney injury (AKI).

CytoSorb in severe rhabdomyolysis

 

CytoSorb® hemoadsorption goes beyond renal replacement therapies – it can help support the recovery of kidney function when conventional strategies to remove myoglobin alone prove ineffective.

 

Hyperinflammation caused by rhabdomyolysis can aggravate AKI and should also be addressed. Early protection of the kidneys helps improve the patient’s prognosis, and early myoglobin clearance may even help prevent AKI.

 

CytoSorb is a unique technology that’s proven to effectively, safely and simultaneously reduce both elevated levels of cytokines and myoglobin, thereby supporting the recovery of renal function.

CytoSorb can be used to address important challenges in severe rhabdomyolysis

Manage rhabdomyolysis

CytoSorb has been shown to effectively and safely remove elevated levels of myoglobin, while additionally addressing any concomitant hyperinflammation, helping in the management of rhabdomyolysis.

Rhabdomyolysis can cause serious damage:

Rapid breakdown of the skeletal muscles
Myoglobin released into the bloodstream
Myoglobin accumulates in renal tubules
Excessive myoglobin levels may result in:
  • Oxidative stress
  • Inflammatory response
  • Endothelial dysfunction
  • Renal vasoconstriction
  • Apoptosis
  • Cellular and granular casts
AKI – Acute Kidney Injury
  • Rapid breakdown of the skeletal muscles
  • Myoglobin released into the bloodstream
  • Myoglobin accumulates in renal tubules
  • Excessive myoglobin levels may result in:
    • Oxidative stress
    • Inflammatory response
    • Endothelial dysfunction
    • Renal vasoconstriction
    • Apoptosis
    • Cellular and granular casts
  • AKI – Acute Kidney Injury

By removal of elevated myoglobin, CytoSorb Therapy can help to restore kidney function:

Effective myoglobin removal
Attenuation of hyperinflammation
Superior performance vs standalone HCO-filter

Best practice therapy management

  • Patient selection
    • Confirmed/ suspected rhabdomyolysis with impending/existing acute kidney injury (AKI)
    • Myoglobin levels > 10,000 µg/L
    • Contraindication for intensified fluid therapy
  • Timing
    • Ideally start within the first 24 hours after diagnosis/onset of severe rhabdomyolysis
    • In general start early before irreversible damage occurs < 12 hours after diagnosis/start of standard therapy
  • Dosing
    • Consider changing adsorber
      after 8 hours until sufficient
      stabilization/clinical
      improvement has occurred or
      myoglobin levels well below
      5000 µg/L have been reached.

Additional Information

  • Albrecht et al., Blood Purif 2024; 53(2):88-95
  • Grafe et al., Ren Fail 2023; 45(2):2259231
  • Scharf et al., Crit Care 2021; 25(1):41
  • Chavez et al., Crit Care 2016; 20(1):135
  • Boutaud et al., Proc Natl Acad Sci USA 2010; 107(6):2699-704
  • Bosch et al., N Engl J Med 2009; 361(1):62-72
  • Khan et al., Neth J Med 2009; 67(9):272-283
  • Chatzizisis et al., Eur J Intern Med 2008; 19(8):568-574
CytoSorbents

Voices around the world

Access Healthcare Professionals Area

This area is for Health Care Professionals only and provides reports about clinical experiences gained during the use of CytoSorbents products. The information presented reflects the opinions and procedural techniques of individual physicians and is not intended as medical advice. Physician experience, risks, patient outcomes and results may vary.